Deulinoleate ethyl is under clinical development by Retrotope and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Deulinoleate ethyl’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deulinoleate ethyl overview

RT-001 is under development for the treatment of amyotrophic lateral sclerosis, progressive supranuclear palsy, infantile neuroaxonal dystrophy (INAD). The drug candidate is administered orally as a capsule. The drug candidate is a di-deuteron synthetic homolog of linoleic acid ethyl ester, an omega 6 polyunsaturated fatty acid and developed using transformational platform technology. It was also under development for Smith-Lemli-Opitz syndrome, Friedreich's ataxia, Alzheimer’s disease, Parkinson’s disease, neuronal ceroid lipofuscinosis like Batten disease, Huntington’s disease, age-related macular degeneration (AMD), diabetic retinopathy, amyotrophic lateral sclerosis, PLA2G6-associated neurodegeneration, Tay Sachs (LOTS), progressive supranuclear palsy and lung damage caused by COVID-19.

Retrotope overview

Retrotope is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases. The company is headquartered in Los Altos, California, the US.

For a complete picture of Deulinoleate ethyl’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.